FDA — authorised 29 December 1986
- Application: NDA019085
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Local brand name: ATROVENT
- Indication: AEROSOL, METERED — INHALATION
- Status: approved
🇺🇸 Atrovent in United States
FDA authorised Atrovent on 29 December 1986
Marketing authorisations
FDA — authorised 20 October 1995
- Application: NDA020393
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Local brand name: ATROVENT
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 20 October 1995
- Application: NDA020394
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Local brand name: ATROVENT
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA — authorised 17 November 2004
- Application: NDA021527
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Status: supplemented
FDA
- Status: approved
Atrovent in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Atrovent approved in United States?
Yes. FDA authorised it on 29 December 1986; FDA authorised it on 20 October 1995; FDA authorised it on 20 October 1995.
Who is the marketing authorisation holder for Atrovent in United States?
BOEHRINGER INGELHEIM holds the US marketing authorisation.